C4 Therapeutics Management
Management criteria checks 2/4
C4 Therapeutics' CEO is Andrew Hirsch, appointed in Sep 2020, has a tenure of 3.75 years. total yearly compensation is $3.79M, comprised of 16.9% salary and 83.1% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $992.58K. The average tenure of the management team and the board of directors is 3.6 years and 6.9 years respectively.
Key information
Andrew Hirsch
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 16.9% |
| CEO tenure | 3.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12
C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors
Sep 29C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M
Aug 04Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00
May 10C4 Therapeutics: Poor Data Destroyed Preclinical Promise
May 04C4 Therapeutics closes $181M capital raise
Jun 21C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial
Jun 14C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy
Jun 07Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%
Jun 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$4m | US$639k | -US$132m |
| Sep 30 2023 | n/a | n/a | -US$135m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$3m | US$614k | -US$128m |
| Sep 30 2022 | n/a | n/a | -US$107m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$952k | US$580k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$21m | US$168k | -US$66m |
Compensation vs Market: Andrew's total compensation ($USD3.79M) is above average for companies of similar size in the US market ($USD2.45M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
CEO
Andrew Hirsch (53 yo)
3.8yrs
Tenure
US$3,790,099
Compensation
Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.8yrs | US$3.79m | 0.31% $ 992.6k | |
| Co-Founder | no data | US$111.41k | 0.46% $ 1.5m | |
| Chief Scientific Officer | 6.1yrs | US$1.53m | 0.34% $ 1.1m | |
| Chief Medical Officer | less than a year | US$1.96m | 0.14% $ 461.6k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| CFO & Treasurer | less than a year | no data | 0.013% $ 42.8k | |
| Chief Accounting Officer | less than a year | no data | 0.0022% $ 7.1k | |
| Chief Legal Officer & Corporate Secretary | 3.9yrs | US$3.38m | 0.014% $ 46.9k | |
| Chief People Officer | 3.4yrs | no data | 0.014% $ 46.9k | |
| Senior Vice President of Strategic Alliances & Business Development | 8.3yrs | no data | no data | |
| Senior Vice President of Chemistry | 3.4yrs | no data | no data | |
| Senior Vice President of Biological Sciences | 5.3yrs | no data | no data |
3.6yrs
Average Tenure
53yo
Average Age
Experienced Management: CCCC's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.7yrs | US$3.79m | 0.31% $ 992.6k | |
| Co-Founder | 8.5yrs | US$111.41k | 0.46% $ 1.5m | |
| Co-Founder & Member of Scientific Advisory Board | 7.6yrs | no data | no data | |
| Lead Independent Director | 8.5yrs | US$157.91k | 0.71% $ 2.3m | |
| Independent Director | 8.5yrs | US$121.91k | 0.038% $ 122.5k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 7.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Chairman | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Director | 2.3yrs | US$126.41k | 0.0082% $ 26.7k |
6.9yrs
Average Tenure
61yo
Average Age
Experienced Board: CCCC's board of directors are considered experienced (6.9 years average tenure).